This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dijkshoorn, L.
Right arrow Articles by Nibbering, P. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dijkshoorn, L.
Right arrow Articles by Nibbering, P. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2004, p. 4919-4921, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4919-4921.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

The Synthetic N-Terminal Peptide of Human Lactoferrin, hLF(1-11), Is Highly Effective against Experimental Infection Caused by Multidrug-Resistant Acinetobacter baumannii

Lenie Dijkshoorn,1* Carlo P. J. M. Brouwer,2 Sylvia J. P. Bogaards,1,2 Alexandr Nemec,3 Peterhans J. van den Broek,1 and Peter H. Nibbering1

Department of Infectious Diseases, Leiden University Medical Center, Leiden,1 AM-Pharma, Bunnik, The Netherlands,2 National Institute of Public Health, Prague, Czech Republic3

Received 19 March 2004/ Returned for modification 7 June 2004/ Accepted 29 August 2004

The lactoferrin-derived peptide hLF(1-11), but not its control peptide, was highly effective against five multidrug-resistant Acinetobacter baumannii strains in vitro (3 to 4 log reduction) and against four of these strains in an experimental infection in mice (2 to 3 log reduction). Therefore, this peptide is a promising candidate as a novel agent against infections with multidrug-resistant A. baumannii.

* Corresponding author. Mailing address: Department of Infectious Diseases, C5-P, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. Phone: 31-71-5262613. Fax: 31-71-5266758. E-mail: l.dijkshoorn{at}lumc.nl.

Antimicrobial Agents and Chemotherapy, December 2004, p. 4919-4921, Vol. 48, No. 12
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.12.4919-4921.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Peleg, A. Y., Seifert, H., Paterson, D. L. (2008). Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin. Microbiol. Rev. 21: 538-582 [Abstract] [Full Text]  
  • Saugar, J. M., Rodriguez-Hernandez, M. J., de la Torre, B. G., Pachon-Ibanez, M. E., Fernandez-Reyes, M., Andreu, D., Pachon, J., Rivas, L. (2006). Activity of Cecropin A-Melittin Hybrid Peptides against Colistin-Resistant Clinical Strains of Acinetobacter baumannii: Molecular Basis for the Differential Mechanisms of Action.. Antimicrob. Agents Chemother. 50: 1251-1256 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»